Recombine’s ChromoMap

0

Genetic tests are quickly gaining the ability to reveal more and more information about your health. There is powerful technology available to provide parents-to-be with information about their future family’s health as they venture into parenthood.

For women who are already pregnant, there are several genetic testing options available; this includes CarrierMap and ChromoMap. Recombine’s CarrierMap can help you plan for a healthy baby, even well before you are expecting as it can also be pursued before pregnancy. CarrierMap gives you insight into you and your partner’s risk to pass on over 200 genetic diseases to your child. Our dedicated genetic counselors help you understand your genetic risks and discuss how knowing more about your genes is a meaningful step in your family planning.

Recombine’s ChromoMap is a noninvasive prenatal test (NIPT) that assesses chromosome health of a fetus at 10 weeks of pregnancy. Twenty-three pairs of chromosomes house all our genetic information, and a number of genetic disorders directly result from too many or too few copies of particular chromosomes. ChromoMap screens for the most common chromosomal abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).

Noninvasive prenatal testing (NIPT), also referred to as noninvasive prenatal screening (NIPS), is performed on a tube of the mother’s blood, typically between 10 and 22 weeks of pregnancy. NIPT is a clever test that takes advantage of a fascinating occurrence in women’s bodies during pregnancy. In this time, about 10-15% of cell-free or, free floating, DNA circulating in the mother’s blood comes from the growing baby! The baby’s DNA can be identified in the lab and analyzed to determine if there is risk in the pregnancy.

As an NIPT test, ChromoMap serves as a screening tool so a positive result must be followed up with diagnostic confirmatory testing via chorionic villus sampling (CVS) or amniocentesis. Additional genetic counseling and consulting with your doctor is a part of that process as well. NIPT is not meant to replace CVS or amniocentesis; however, it can guide women’s decision regarding whether to move forward with invasive diagnostic procedures.

With Recombine, couples can find prenatal genetic testing and counseling in one place. Taking a closer look at your or your baby’s genes with our CarrierMap and ChromoMap tests allows you to make medical decisions that are right for your family’s health.

Share.

About Author

Stephany Foster

Stephany Foster is the Associate Scientific Writer at Recombine, a genetic testing company based in New York City. She writes on topics spanning fertility, reproductive medicine, and recent advances in genomics. Stephany also writes about recently published research that Recombine presents at conferences and meetings around the globe. Before joining Recombine, Stephany interned at the George Church Lab at Harvard Medical School. She graduated from Brown University with an A.B. in Biology in 2014.